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Abstract 
Many methods have been used to study calcium 
oxalate crystallisation. Most can be characterised by 
changes in supersaturation during the experiment, which 
may increase, remain constant or decay. Their ability to 
quantify various aspects of crystallisation often reflects 
the extent to which nucleation, growth and aggregation 
can be measured independently, when two or three of 
these processes may be occurring simultaneously. 
The mixed suspension , mixed product removal 
technique reaches a steady state supersaturation, is a 
good model for intrarenal crystallisation and allows both 
growth and nucleation rates to be measured. Using 92% 
urine and comparing control urines with samples from 
recurrent stone formers no difference in growth rates 
was found but the controls had higher nucleation rates 
(p=0.003) and lower supersaturations (p=0.001). In 
parallel crystallisers running simultaneously , heparin or 
hyaluronic acid addition to 92% urine was studied. 
Both macromolecules increased growth rates, decreased 
nucleation rates and increased supersaturation (p<0.05). 
The steady state supersaturation achieved in this 
system may be an important determinant of stone 
forming potential. The ability to reach a lower urinary 
supersaturation by increased nucleation may be a crucial 
protective factor distinguishing non stone formers from 
stone formers. 
KEY WORDS : Calcium oxalate, crystallisation, 
urolithiasi s, crystal nucleation, crystal growth. 
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Introduction 
Many different methods have been used to study 
calcium oxalate crystallisation, some differing in 
technical detail and others at a more fundamental level. 
Alternative approaches enable different types of 
measurements to be made which may be most 
appropriate for particular applications to urolithiasis 
research; on the other hand, lack of standardisation of 
methods used may be at least partly responsible for 
contradictory results reported from apparently similar 
experiments (Ryall et al., 1986a). 
In order to appreciate the potential of different 
methods , it is important to remember the underlying 
processes involved in stone formation . These essentials 
have been well described (Finlayson, 1978; Ryall, 1989) 
as crystal nucleation, crystal growth (by precipitation of 
fresh crystalline material from the surrounding liquor) 
and crystal aggregation. Inhibition or promotion of any 
of these processes in urine will reduce or enhance the 
likelihood of stone formation and have therefore become 
the focus of many in vitro urolithiasis studies (Fleisch, 
1978). Supersaturation is a prerequisite for 
crystallisation. Two states of supersaturation have been 
identified, a metastable state where crystallisation does 
not occur unless perturbed by the addition of seed 
crystals and an unstable state where crystallisation 
occurs spontaneously . A metastable solution of calcium 
oxalate can be forced into an unstable state by the 
addition of more calcium or oxalate in the form of 
dissolved salts. 
This paper will review the more commonly used in 
vitro techniques, discuss the principles by which they 
operate, their strengths and weaknesses and identify 
their role in the study of calcium oxalate crystallisation 
and stone formation. It will also include some new 
results obtained with a continuous flow method , 
modified to be applicable to nearly whole urine . 
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Review of Methods 
Background Comments 
Methods for studying calcium oxalate 
crystallisation can broadly be divided into three main 
types, depending on how the supersaturation changes 
during the course of the experiment (Fig. 1). Firstly , 
the supersaturation may be allowed to decay; here 
crystallisation is induced and allowed to proceed without 
any further additions and the supersaturation of the 
solution decreases as calcium oxalate crystallises. 
Secondly, the supersaturation may be increased. In this 
approach, initially stable solutions are concentrated to 
induce crystallisation, with the aim of reproducing the 
way the kidney brings about supersaturation. In the 
third approach, constant supersaturation is maintained. 
Calcium and oxalate are continuously added, again with 
the intention of generating a better model of intrarenal 
crystallisation than supersaturation decay systems. 
Each of these three distinct approaches can be 
applied in many different ways with different aims. 
Crystallisation may be allowed to occur from simple salt 
solutions, complex mixtures which mimic urine or urine 
itself. When urine is included it may be very dilute , 
undiluted or concentrated. The objectives of these 
experiments are to better understand the physico-
chemical processes, to study the effects of certain well 
defined chemical components and to investigat e the 
influence of urine derived macromolecules and/or to 
compare urines from differ ent patients. A possible 
application which has not been widely used is to 
examine the value of potential therapeutic agents in vitro 
with the urine of individual stone forming patients in 
order to identify those most likely to benefit from a 
particular treatment regime. This could be particularly 
fruitful bearing in mind that any prophylactic regime 
may have to be pursued for many years. After all, the 
purpose of these experimental studies is to prevent stone 
disease. 
A variety of parameters may be measured by 
different techniques , for example, the metastable limit 
(onset of nucleation), nucleation rate, growth of crystal 
mass as a whole or distinct from nucleation , growth of 
crystal size which may include aggregation effects, 
kinetic rate constants , inhibitor/promoter activities and 
Langmuir adsorption isotherms. Apparently similar 
parameters measured by different methods may yield 
different results and have quite distinct meanings . On 
the other hand, different groups have used different 
nomenclature and formulations to express equivalent or 
similar parameters . 
686 
Supersaturation Decay Systems 
Seeded Crystalliser Systems (Fig. 11 curve a) 
General comments. One of the most common 
approaches to the study of calcium oxalate 
crystallisation uses a metastable supersaturated solution 
of calcium oxalate in which crystallisation is initiated by 
the introduction of calcium oxalate monohydrate seed 
crystals. The crystallisation process can be monitored . 
by observing the size and number distribution of the 
particles in suspension (Robertson & Peacock, 1972; 
Robertson et al., 1973) or by following either calcium 
(Meyer & Smith, 1975a) or oxalate (Ito & Coe, 1977; 
Ligabue et al., 1979) depletion from solution or calcium 
or oxalate incorporation into the solid phase (Will et 
al., 1983). Radioactiv e calcium or oxalate or 
conventional chemical analysis may be used or the 
reaction can be followed by conduc~vity (Nancollas & 
Gardner, 1974), calcium ion electrode (Baumann et al., 
1990) or absorbance due to oxalate at 214nm 
(Nakagawa et al., 1987). 
In such seeded crystalliser systems, nucleation 
should not occur, while both crystal growth and 
aggregation may be taking place simultaneously. When 
the particle size and number distribution is monitored 
then both crystal growth (precipitation of fresh solid 
phase) and aggregation will be reflected in the results, 
but when calcium or oxalate removal from the solution 
or incorporation into the solid phase is followed, only 
crysta l growth is usually considered. 
A frequent aim of crystallisation studies is to 
quantify the ability of urine or particular components to 
inhibit some aspect of the crystallisation process. This 
is often achieved by comparing results under test 
conditions (R_test) with a control experiment (R_ctl) and 
defining the % inhibition as 
I% = (l-(R_testlR-ctl)) x lOO (l) 
or 
I% = ((R_cu-R-test)IR_ctl) x JOO (2) 
It should be noted that equations 1 and 2 are equivalent. 
Growth and aggregation considered as a combined 
process. When particle size analysis of seeded 
crystalliser systems was first applied in the context of 
kidney stone research , no attempt to distinguish growth 
and aggregation processes was made. Instead these 
were considered as combined effects by measuring the 
increase in volume of only those particles greater than 
20µm, 4 hours after seeding. Solutions containing test 
inhibitors (Robertson et al., 1973), 5% urine (Robertson 
& Peacock, 1972) or 1 % urine (Robertson et al. , 1976) 
were then compared against a saline control, allowing 
the degree of inhibition , 1%, to be calculated. 



















Figure 1. Diagrammatic representation of supersaturatio n changes that could occur in different methods for 
studying calcium oxalate crystallisation; a, seeded, metastable system with supersaturation decay; b, 
supersaturation raised above the metastable limit and allowed to decay; c, supersaturation increased by 
evaporation; d, supersaturation increased by reverse osmosis; e, supersaturation increased by diffusion (e1, 
unseeded , e2, seeded); f, constant composition system; g, mixed suspension, mixed product removal method . 
The grey scale represents the ill defined boundary between metastable and unstable supersaturation. 
Growth and aggregation considered as separate and 
independent processes. Ryall et al. (1981a) showed that 
a given value of I% could result from very different 
combinations of growth inhibition and aggregation 
inhibition. This was achieved by considering growth and 
aggregation to be independent of each other and treating 
volume changes as being due to growth and changes in 
particle numbers as a result of aggregation. They 
applied this approach to dilute urine (2 to 10%) (Ryall 
et al., 1981b) and to 1 % urine and various inhibitors 
(Ryall et al., 1981c) . They found that the time (t) 
course of volume changes (~ V) and particle number 
changes (~ were non-linear, which led them to 
criticise the use of an arbitrary fixed time for comparing 
control and test experiments (Ryall et al., 1981b and 
1981c). They overcame this problem by plotting t/~V 
against t and t/LiN against t, which gave straight line 
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plots, from which the initial rates (~ V /4=0 and LiN/1t=o) 
were found from the reciprocals of the intercepts on the 
y axes at t=O. Inhibition of growth (lg%) and 
aggregation (Ia%) were then calculated by comparing 
test and control data. 
This approach was elaborated upon, to take into 
account particles growing or aggregating into or out of 
the size range measured by the particle analyser (Ryall, 
RG et al. , 1986) and has been applied to experiments 
including 1 % urine or inhibitors (Ryall , RL et al., 
1986b). 
Growth considered as an independent process. 
Some workers have considered growth and aggregation 
in seeded systems to be independent of each other and 
have therefore studied crystal growth kinetics simply by 
following calcium or oxalate changes. In crystal seeded 
metastable systems, calcium oxalate crystallisation is 
KAVANAGH, JP. 
usually found to follow second order reaction kinetics 
with the rate of reaction being proportional to the square 
of the driving force for crystallisation (relative 
supersaturation, RS), 
2 
-dRS/dt = K(RS-1) (3) 
where K is a rate constant (Finlayson, 1978; Curreri et 
al ., 1981). 
Generally , when working within restricted ranges 
of conditions, it has been possible to simplify equation 
(3) to calcium activities (Nancollas & Gardner, 1974; 
Meyer & Smith 1975a), calcium concentrations (Ito & 
Coe, 1977) or oxalate concentrations (Ligabue et al., 
1979), for example, 
2 
-dM/dt = K([Mtl-[Mt=eqD (4) 
where [Mtl and [Mt=eql are the solution concentrations 
or activities of calcium or oxalate at time t and at 
equilibrium, respectively. 
This description of the crystal growth kinetics 
allows quantitative comparisons of related experiments 
to be expressed in various ways. A simple approach is 
to measure the decrease in calcium or oxalate between 
the initial time and some fixed time (~[Mlt). (For 
example, t=40 minutes , Ito & Coe, 1977; t=2.5 hours , 
Ligabue et al., 1979; t=4 hours, Koide et al ., 1981; t=I 
hour , Fellstrom et al., 1982). The % inhibition can then 
be calculated as, 
I% = (l-(MM]t testl~[M]t cti)) x lOO (5) 
or when a rate constant (K) is calculated, as, 
I%= (1-(K_testlK-ctl)) x 100 (6) 
In order to calculate the rate constant K (in 
equation 4) , some estimate of [½=eql can be made and 
calcium or oxalate measured at time intervals . K can 
then be conveniently obtained from the slope of the 
straight line plot of 1/([Mt]-[Mt=e<J]) against t. Meyer 
& Smith (1975a) and Ito & Coe (1977) measured the 
solubility product under their experimental conditions by 
allowing dissolution or crystal growth experiments to 
reach equilibrium and used the average of these values 
to calculate [½=eql · The amount of calcium or oxalate 
at a fixed time has been taken to approximate to the 
equilibrium position. (For example, 4 weeks , Gill et al., 
1977; 24 hours, Ligabue et al., 1979; 3 hours , Fellstrom 
et al., 1982). An alternative is to use nonlinear 
regression to the [M] versus t data to give estimates of 
Kand [½=egl (Nakagawa et al., 1981, 1985). Rather 
than collect data at many time points, a single time and 
the equilibrium value can be used to obtain a simplified 
estimate of K, as, 
K = ~[Mtl/[½=eql (7) 
as before, different methods of estimating [Mt=e ] are 
possible (Gill et al., 1977; Tiselius & Fornander, itJ81) . 
However they are calculated, these rate constants 
688 
are empirical and will reflect particular experimental 
conditions such as temperature (usually 37C), ionic 
strength and the quality and surface area of the seed 
crystals. If a tested inhibitor significantly associates 
with calcium or oxalate, then this should be taken into 
account by using activities rather than concentrations in 
equation 4 (Meyer & Smith, 1975b) . 
The % inhibition obtained from equations 5 or 6 
can be used to make comparisons of different inhibitors 
at the particular concentrations tested, or to infer the 
relative amounts of inhibitor under particular 
circumstances. This can be useful in following inhibitor 
activity through a purification procedure (e.g. Ito & Coe, 
1977; Nakagawa et al., 1981), examining the effect of 
some treatment of an inhibitor (e.g. Fellstrom et al., 
1982) or comparing urines at a fixed dilution (e.g. 2%, 
Ligabue et al., 1979). When comparing different 
inhibitors and trying to gauge their likely significance in 
vivo, it is important to consider the extent of inhibition 
over a range of concentrations. The use of Langmuir 
adsorption isotherms can be helpful in this respect, 
particularly as this can give some insight into the 
mechanism of inhibition. 
Langmuir adsorption isotherms will apply if growth 
inhibition is achieved when the inhibitor blocks growth 
sites by binding to the seed crystals and adsorption of 
further inhibitor is dependent only on the number of free 
sites available, in which case simple saturation kinetics 
will be obeyed , 
0 = k[I]/( 1 +k[n) (8) 
where 0 is the proportion of sites occupied, k is an 
adsorption coefficient and [I] is the inhibitor 
concentration. If the crystal growth rate is proportional 
to the number of free sites (1-0) then 
[I] = CKcffKtest)fkKctl + 1 (9) 
or 
[I] = (Kcti-Ktest)fkKrest (lO) 
and a plot of Kct1f<Kcti-Ktest) against 1/[I] (e.g. Meyer 
& Smith, 1975b; Nakagawa et al. , 1981)) , KresJCKctl -
Ktest) against 1/[I] (e.g. Nakagawa et al., 1985) or 
Ln((Kctl - Krest)IK1est) against Ln[I] (Kok et al., 1986a) 
will be a straight line with k obtained from the slope 
(first two plots) or intercept (log plot). A good fit of 
experimental data to such a line supports the mechanism 
of inhibition of blocking growth sites by reversible 
binding and k is an indication of the potency of the 
inhibitor, being the concentration required to halve the 
growth rate in the absence of inhibitor. Meyer & Smith 
(1975b) proposed this method for comparing the 
inhibition due to different components and for 
quantifying the inhibition of different urine samples. 
This would require measuring rate constants (Ktest) for 
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a variety of dilutions of urine and has been applied to 
urine with and without various inhibitors (Wemess et 
al., 1981) 
When urine has been studied in seeded 
crystallisers, it has usually been diluted to between 1 % 
and 10%. This is because of the high inhibitory power 
of urines in these systems and the requirement to have 
the initial supersaturation close to control values, which 
is not simply a matter of matching initial calcium and 
oxalate concentrations . Baumann et al. (1990) have 
tried to overcome these problems in a study using whole 
urine . In order to promote sufficient and rapid 
crystallisation, they seeded their system with a high seed 
concentration and followed the reaction with a calcium 
ion electrode . They evaluated their results as h, the 
time taken to reduce the calcium ion activity to half the 
decrease over 20 minutes, by which time the reactions 
appeared to be complete. The inhibitory effect of urine 
or inhibitors was calculated as the increase in h 
compared to a control experiment (htest-'hcu), which 
appeared not to be strongly dependent on the urinary 
concentration of calcium or oxalate. 
Growth and aggregation considered separately but 
not independently. The studies described above (and 
many others) have taken the changes in calcium or 
oxalate during the course of the experiment to be 
representative of crystal growth only . This assumption 
has been questioned (Blomen et al., 1983) . In a 
thorough series of experiments Will et al. (1983) , 
Blomen et al. (1983) and Bijvoet et al. (1983) have 
developed a general equation for calcium oxalate growth 
in a metastable solution , se1fd with calcium oxalate 
crystals. In their system Ca is included in the 
metastable solution and its incorporation into the solid 
phase is quantified at intervals and represented by the 
fractional uptake (Ut) at time t, 
Ot = ([Mt=oJ-fMtD/[Mt=oJ C11) 
where [~=o] is the initial calcium concentration . 
Second order kinetics were observed as previously, 
expressed as, 
dU/dt = UJlm((U 00 -Ul)/U 00 l (12) 
where U
00 
is the maximum fractional uptake of calcium 
that would occur for a particular experiment. The time 
taken for the uptake to reach 50% of this value is lm· 
(This therefore corresponds to the half time, h used by 
Baumann et al ., 1990). U
00 
can be obtained as the 
reciprocal of the slope of the straight line plot of t/Ut 
versus t, while lm is found from the intercept on the 
t/Ut axis (lm/U 00 ) (Will et al., 1983). If U00 is 
comparable to [~=eq1 in the same way as U1 and [M1] 





in equation 12 is proportional to ([~]-[Mt=eqD 2 in 
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equation 4 and UJlm is an empirical rate constant 
related to K. In the following two papers of this series 
(Blomen et al., 1983 & Bijvoet et al. , 1983), the 
relationships between UJlm and the crystal seed 
concentration , the initial supersaturation, ionic strength 
and calcium to oxalate ratio were explored. This led to 
the formulation of a comprehensive explanation of the 
growth rate, 
dU/dt = kAs[U 00 ] x 2 2 
([C3t=o]/[C3t=eq1+[Ox 1=ol/[ Oxt=eqD ( (U 00 -Ut)/U 00 ) 
(13) 
where s is the crystal seed concentration, kA is the 
crystal growth constant and [U
00
] is maximum fractional 
uptake predicted from the initial and equilibrium 
concentrations of calcium and oxalate . Considering 
equations 12 and 13, the empirical rate constant for a 
particular set of experimental conditions is explained, 
UJlm = kAs[U 00 ] x 
2 
([C3t=o)/[C3t=eql+[Oxt=O]/[Oxt=eqD (14) 
and rearranging this kA is found from equation 15 (Kok 
et al., 1988). 
1/k A = ([Uoo]Slm/Uoo) x 
2 
( [ C3t=o]/[ Cat=eq1 + [ Oxt=o]/[ Oxt=eq]) ( 15) 
The equilibrium concentrations ([C3t=eqL[Ox 1=eqD 
are found from a series of separate experiments w~ch 
identify the minimum concentration at which 
4 
Ca 





and lm are obtained from the 
growth curve as described above (Will et al. , 1983). 
Once k A is found for test and control conditions the % 
growth inhibition is readily calculated. 
The crucial difference between the approach of this 










was most pronounced at low seed 
concentrations and has been attributed to aggregation 
(Blomen et al ., 1983). They were able to quantify this 
effect by the parameter [lm], the time when uptake 
reaches 50% of [U
00
]; 
[lm] = lm([Uoo]/([U00 J-U00 )) (16) 
which increases with inhibition of aggregation . 
The suggested mechanism for the influence of 
aggregation on the initial supersaturation and hence on 
the growth kinetics by reducing U
00 
was that the 
solution included within aggregates might not be 
representative of the bulk solution and some of the 
crystal growth surfaces would be exposed to lower 
supersaturations than expected from the calcium and 
oxalate concentrations (Kok et al., 1988). Some 
justification for using [lml to describe the aggregation 
during the progress of a crystal growth experiment 
comes from analysis of particle size distributions in the 
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same system (Kok et al., 1988). Further support can be 
seen by comparing Langmuir plots where k A is used or 
when I% (as in equation 5) is calculated using the 
fractional calcium uptake at a fixed time (20min). 
Using k A gives a linear plot over a wider range of 
inhibitor concentrations than does I% (Kok et al., 
1986a). 
Crystal growth and aggregation have been 
measured using this method to study the effect of 
inhibitors (Kok et al., 1988), of urine (20%) (Kok et al., 
1986b, 1990a) and effects of dietary changes on urine 
(Kok et al., 1990b). Some difficulties in interpretation 
can arise if a compound is an inhibitor of both processes 
(for example, citrate) because they are not independent. 
A problem with 11ml as an indicator of aggregation is 
that the increase associated with inhibition of 
aggregation is not linear and 11ml would tend to become 
infinite at 100% inhibition of aggregation. Nevertheless, 
11ml adds an extra dimension to the study of calcium 
oxalate crystallisation in seeded systems. 
It is not yet clear how the interpretation of 
experiments might be affected where the effect of 
aggregation on crystal growth kinetics was not taken 
into consideration. Inhibition of aggregation might 
diminish the apparent growth inhibition estimated by 
these methods, with any effects expected to be more 
pronounced at low seed concentrations. The means of 
determining [Mi=eql can now be seen to be critical. In 





and in others to an average of both. The 
effect of lack of independence between growth and 
aggregation may need to be examined on particle size 
distribution data, where the analysis assumed they were 
independent. 
Concluding comments on seeded, supersaturation 
decay systems. Crystallisation with supersaturation 
decay , induced by crystal seeding, has been one of the 
most widely used techniques for studying calcium 
oxalate monohydrate crystallisation in vitro. It is 
usually performed in simple buffered saline and the 
accuracy and reproducibility that can be achieved make 
it very useful in investigating the interactions between 
possible inhibitors and the crystallisation processes of 
growth and aggregation, in the absence of nucleation. 
The ability to fit crystallisation data from these 
experiments to simple equations gives confidence that 
the extrapolated rate constants and percentage inhibition 
values relate directly to some well defined physico-
chemical process . To take full advantage of this care 
must be taken to be clear how rate constants and 
equilibrium values have been calculated or estimated. 
The relevance of measurements made in saline or 
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dilute urine to urinary stone formation has been 
questioned by many authors (Fleisch, 1978; Robertson 
et al. 1981; Ryall et al., 1986a). As methods have 
evolved, comparisons with previous studies becomes 
more difficult. It is unfortunate that similar terminology 
has sometimes been used to cover different 
measurements, while different but equivalent expressions 
of the same formulae may give rise to further confusion. 
Non Seeded Crystalliser Systems (Fig. 11 curve b) 
General comments. Crystallisation can be induced 
in simple salt solutions or urine by increasing the initial 
supersaturation usually by the addition of oxalate in 
solution. In these systems , nucleation, crystal growth 
and aggregation may all occur simultaneously as the 
supersaturation declines to an equilibrium value. The 
progress of the crystallisation can be followed, as 
before, by various means, such as measurement of 
calcium by specific ion electrode, calcium or oxalate 
determinations chemically or with radioactive tracers 
(Gill et al., 1977; Rose, 1975; Garti et al., 1980; Koide 
et al., 1981; Sarig et al., 1982), particle counting and 
sizing (Robertson et al., 1981; Ryal! et al., 1985; 
Tiselius , 1985), microscopic evaluation of crystals 
(Grases et al., 1988), nephelometry (Sutor et al., 1979; 
Grases et al., 1988) or visual estimation of turbidity 
(Kohri et al., 1991). 
The main problem with these methods is that 
interpretation of the measurement s is more difficult than 
with seeded systems. This is because aggregation and 
growth will be dependent on the crystal surface area 
(which will increase as a result of nucleation and growth 
and decrease due to aggregation) and all three processes 
will depend, to differing degrees , on the declining 
supersaturation. In practice it is not possible to 
distinguish rigorously between these different aspects of 
crystallisation and attempts are not usually made to 
measure physico-chemically meaningful rate constants. 
As a consequence, the choice of experimental conditions 
is often arbitrary and direct comparisons between 
different methods can not necessarily be expected to be 
valid. 
At the supersaturations usually found in urine, 
precipitation of calcium oxalate on surfaces and particles 
unavoidably present in the crystalliser (heterogeneous 
nucleation) is likely to predominate over direct 
formation of calcium oxalate nuclei (homogeneous 
nucleation) (Finlayson, 1978). When whole urine is 
used, even if filtered, a highly variable concentration of 
heterogeneous nucleators are likely to be introduced. 
Metastable limits and nucleation tendency . The 
supersaturation at which spontaneous nucleation and 
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growth occur may be found by increasing the 
concentration of oxalate (Pak & Holt, 1976; Ryall et al., 
1985; Tiselius, 1985) or oxalate and calcium (Gill et al., 
1977; Kohri , 1991). This supersaturation is usually 
referred to as the metastable limit or as a formation 
product. This concept does not have a strong theoretical 
foundation (Finlayson, 1978) because it can not be 
equated to an exact calcium and oxalate activity product. 
Any estimate will depend on the method used to detect 
significant crystallisation and the induction time allowed 
for this precipitation to begin. 
The initial burst of crystallisation will produce 
particles too small for detection directly, or for 
separation and quantification by chemical means . 
Detection of the onset of crystallisation is thus limited 
by the sensitivity of the method and will only be 
triggered when crystals have also grown (and possibly 
aggregated) sufficiently large to be measured . 
Therefore, a rapidly growing/aggregating suspension 
with a low nucleation rate may give a similar metastable 
limit to a rapidly nucleating, slowly growing/aggregating 
mixture. 
The general approach to measuring a meta<;table 
limit is to set up aliquots with increasing supersaturation 
and determine the minimum value at which 
crystallisation is observed at a fixed time (for example, 
3 hours - Pak & Holt (1976); 30 minutes - Ryal! et al. 
(1985); 5 minutes - Kohri et al. (1991) and various 
times from hour s to days - Pak et al. (1975) and Gill et 
al. (1977). It is to be expected that the measured 
metastable limit would decrease if the observation time 
is increased (as shown by Pale et al. (1975) and Gill et 
al. (1977)). 
Tiselius (1985) has used a slightly more complex 
method of carefully timed addition of oxalate , 
observation (2 minutes later) and repeating the cycle 
with further additions of oxalate (5 minutes after the 
previous addition). This method was applied to filtered 
urine , diluted to a fixed creatinine concentration (5mM), 
or to 80% of its original concentration and the calcium 
oxalate crystallisation risk (CaOx-CR) was defined as 
the reciprocal of the oxalate concentration required to 
bring about an initial burst of crystallisation. Baumann 
(1988) has described a similar method to identify the 
minimum oxalate concentration required to induce 
precipitation; an oxalate solution is continually infused 
into a calcium solution or urine, with the crystallisation 
followed by nephelometry. Another variation, which 
takes into account the endogenous urinary calcium by 
comparison with an artificial urine standard curve, is the 
oxalate tolerance test (Briellmann et al., 1985; Hering, 
1988). 
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The amount of calcium or oxalate that must be 
added to reach the metastable limit should depend on 
the initial supersaturation as well as other factors. It 
would be expected to decrease with increasing initial 
supersaturations which is supported by the results of 
Tiselius (1985) and Ryal! et al. (1985 and 1986a). Pak 
& Holt (1976) take this into account by relating their 
measured formation product to an empirically 
determined activity product ratio (an estimate of 
supersaturation) and call this the Formation Product 
Ratio (FPR). Ryal! et al. (1986a) expressed their 
results as both the rise in oxalate required to bring about 
crystallisation and the product of the concentrations of 
calcium and total oxalate (i.e. endogenous oxalate plus 
that added). 
Measurements of metastable limits as an indicator 
of nucleation have been used to examine the effects of 
various additions to simple salt solutions (Pale et al., 
1979), artificial urine (Gill et al., 1977), or whole urine 
(Ryall et al., 1991). Urines from different patients (Pak 
& Holt, 1976; Pale & Galosy , 1980; Ryall et al., 1985, 
1986a; Tiselius, 1985) have been compared and 
modification of whole urine by ultrafiltration (Edyvane 
et al., 1987) or urate removal (Grover et al., 1990a) or 
urate addition (Grover et al., 1990b) have been studied. 
Although these methods for studying nucleation 
tendency are not solely dependent upon nucleation they 
have the great advantage of being able to be applied 
simply to whole urine . Without taking into account the 
initial supersaturation, direct comparisons between 
samples may not be appropriate and practical variations 
in the applications of the methods are likely to exert 
considerable influence. 
Crystallisation from above the metastable limit. 
The effect of inducing crystallisation by rapidly raising 
the supersaturation and then allowing it to decay may be 
evaluated by following the time course of events or by 
taking measurements at some arbitrary fixed time or 
when crystallisation is almost complete. The difficulty 
in interpreting these results in terms of the different 
aspects of crystallisation has meant that the conclusions 
often drawn are only general. For instance, Garti et al. 
(1980) compared the time course of calcium activity 
decay in artificial urine by adding inhibitors and 
concluded that retardation of crystallisation by these 
inhibitors is not identical with inhibition of 
crystallisation, as the same end point could be reached. 
The extent of crystallisation at a particular time 
after initiation of nucleation can be used to give an 
indication of the crystallisation potential of artificial 
urine or dilute urine (Rose , 1975; Sutor et al., 1979) 
and the inhibitory activity characterised by comparison 
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with control experiments. Sarig et al. (1982) defined a 
discrimination index (DJ .) as the log of the ratio of 
calcium activity at two different times (0.5 minutes and 
10 minutes), 
DJ.= Ln([~=o .51/[Mt=lO]) (17) 
They used this to compare urines diluted to 10% of their 
initial concentration and to study the effect of urinary 
ultrafiltration (Azoury et al., 1985). The discrimination 
index was felt to reflect the inhibitory potential of 
different samples. 
Rather than use a single time or pair of time 
points, Grases et al. (1988) used the initial rate of 
increase in turbidity in 89% urine as a measure of 
crystallisation and Bek-Jensen & Tiselius (1991) used an 
empirical integral of the decay in oxalate in solution 
over 30 minutes. 
In a method designed to focus upon aggregation, 
Koide et al. (1981) allowed the crystallisation to 
continue for a much longer time (24 hours) after which 
they determined the proportion of the total oxalate 
precipitated (M_ppt) that was found in particles greater 
than about 20µm and used this to calculate a non 
aggregated ratio (NAR), 
NAR = M_ppt(>20µm)/M_ppt (18) 
Ryall et al. (1985) have tried to obtain a better 
insight into the time course and nature of the non 
seeded crystallisation in urine by measuring particle 
size distributions. In this method whole urine is used 
and the amount of oxalate added to induce 
crystallisation was 0.3 mM above the previously 
determined metastable limit. They used the slope of the 
linear portion of the volume data as a measure of crystal 
growth rate. This is analogous to the treatment of 
particle size distribution data from seeded crystalliser 
experiments (Ryal! et al., 1981c), but growth rates from 
the two systems should not be confused as the non 
seeded system includes nucleation effects. The changes 
in particle numbers can not similarly be ascribed simply 
to aggregation, as had been done before, again because 
of nucleation. 
In a subsequent report Ryall et al. 1986a suggested 
that the total crystal volume after 90 minutes is another 
indicator of crystal growth and the peak size of the 
particle distributions gives an indication of the extent of 
aggregation. This method has been applied in a number 
of studies with whole urine (Edyvane et al., 1987; 
Grover et al., 1990a, 1990b; Ryall et al., 1991) and, in 
combination with the determination of a metastable 
limit, it has been possible to draw general conclusions 
about the effect of an experimental treatment on 
nucleation, growth and aggregation. 
In a non seeded crystallisation experiment the 
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choice of conditions is likely to have a significant effect 
on the outcome. The nucleation and growth rates will 
depend on the supersaturation chosen to initiate 
crystallisation which may in tum indirectly influence the 
degree of aggregation that occurs. During the initial 
period, nucleation will dominate over growth and 
aggregation and this balance will continue to vary as the 
supersaturation decreases , with aggregation possibly 
being the predominant process as equilibrium 
approaches. If the aim of an investigation is to study 
the effect of components in a well defined medium, non 
seeded crystallisation experiments have little to offer in 
comparison with seeded systems. The exception is 
when a study of nucleation effects is planned. In 
experiments aimed at the study of whole urine, the 
approach of Ryal! et al. (I 985) with a consistent choice 
of starting supersaturation has much promise . 
Increasing Supersaturation Systems 
General comments. This group of techniques is 
distinguished from those already described because the 
method for increasing the driving force for 
crystallisation continues to be applied while precipitation 
is taking place . Of course, when crystals start to form 
this will tend to reduce the supersaturation and the 
actual supersaturation during an experiment is unlikely 
to be well defined. 
It could be argued that some of the methods 
already discussed above should belong in this section as 
they used intermittent (Tiselius, 1985) or continuous 
addition of oxalate solution (Baumann, 1988; Briellmann 
et al., 1985, Hering, 1988). Although some growth and 
aggregation would be taking place during these additions 
of oxalate , these studies were concerned mainly with 
nucleation and were only pursued until the crystals 
reached the chosen detection limit. 
Concentration by Evaporation (Fig. 11 curve c) 
Rapid evaporation of urine at 37C to a fixed 
osmotic pressure (l.2osm/l) has been used to induce 
crystallisation (Hallson & Rose, 1978) with the sample 
being examined microscopically or chemically after 
standing at 37C for one hour after concentration. When 
calcium oxalate crystals were produced they were 
mainly the dihydrate form often seen in urine. This 
method has been used to compare fresh urine from stone 
formers and control subjects (Hallson & Rose, 1978; 
Azoury et al., 1987) and can be used to examine effects 
of ultrafiltration or various additions (Hallson & Rose, 
1979; Hallson et al., 1982 & 1983; Rose & Sulaiman, 
1982 & 1984a & b; Grover et al., 1990c) . The 
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observed crystalluria may be in response to hetero-
geneous nucleators or homogeneous nucleation as a 
result of the increased supersaturation. The change in 
saturation for each urine will of course vary depending 
on their initial saturation and osmotic pressure. 
Although not amenable to rigorous analysis of 
nucleation, crystal growth or aggregation, the method 
has two distinct advantages. It can be used with fresh 
whole urine and the concentration procedure may mimic 
the water reabsorption that occurs in the upper part of 
the urinary tract as the urine is formed. 
Concentration by Reverse Osmosis (Fig. 1, curve d) 
Another method which aims to reproduce intrarenal 
development of supersaturation is reverse osmosis 
(Azoury et al., 1986a, b & c). In these studies feed 
solutions of calcium and oxalate, below supersaturation, 
were forced at high pressure through hollow fibre 
reverse osmosis membranes which are permeable only 
to water . This is a continuous flow procedure and can 
be so arranged as to have a transit time through the 
apparatus comparable to transit times through the renal 
tubules (about 3 minutes). The water reabsorption 
during this time was about 80% which generated 
sufficient supersaturation to induce crystallisation, again 
mainly of the dihydrate form. The crystals produced 
were counted and sized and examined by scanning 
electron microscopy and the composition of the output 
stream analysed . The effects of some inhibitors were 
examined in this system (Azoury et al., 1986a & b). 
Apart from some effects on crystal numbers, changes in 
the hydration habit of the crystals and extent of 
aggregation were also noted . The main advantage of 
this technique is that it may provide a good model for 
generation of supersaturated urine within the kidney, 
however, it would not be easy to analyse nucleation, 
growth and aggregation processes separately. 
Supersaturation Increased by Diffusion (Fig. 11 
curves e1 and ei.>. 
Although not very widely used, it is possible to 
raise the supersaturation of a test system by allowing 
calcium or oxalate, or both, to diffuse into it. When this 
approach has been used, the crystal products have 
usually been immobilised by forming on glass fibre or 
in a gel. In the glass fibre method a thread is 
suspended in a vessel containing urine or buffer and 
calcium and oxalate allowed to diffuse in via two filter 
paper wicks. The resulting crystallisation can be 
quantified by weighing the wick, dissolving the crystal 
products and measuring calcium or measuring the 
calcium in solution (Sutor, 1969; Dent & Sutor, 1971; 
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Welshman & McGeown, 1972; Sallis & Lumley, 1979). 
In these studies, crystallisation was allowed to proceed 
for many hours and the net result will reflect nucleation, 
aggregation and growth. 
In gel systems, calcium and oxalate can be allowed 
to diffuse towards each other through an agar gel and 
crystallisation will occur at the boundary where they 
meet. This can be quantified by changes in turbidity 
and inhibitors or urine effects can be examined by 
permitting them to diffuse into the crystallisation zone 
(Roehrbom et al., 1986) . Another method is to include 
oxalate and seed crystals in a gel and place the calcium 
containing solution (which may be urine) above it. 
Again diffusion will bring about supersaturation and the 
crystallisation can be followed by the increase in 
turbidity of the gel (Achilles et al., 1991). These 
techniques can be easily applied to measure many 
different samples . The relative diffusion rates of 
different macromolecular components of the urine may 
compromise these comparisons . On the other hand, 
large crystals may form, which, as they are immobilised, 
could be relevant to mechanisms that enable crystals 
within the kidney to become sufficiently large to 
become a clinical problem. 
Constant Supersaturation Systems 
Constant Composition Crystallisers (Fig. 1, curve 0 
Crystallisation of calcium oxalate and stone 
formation in the kidney takes place in an environment 
with a relatively constant supersaturation. Tomson & 
Nancollas ( 1978) developed a technique to reproduce 
this in vitro, which Sheehan & Nancollas (1980) applied 
to studies of calcium oxalate monohydrate crystal 
growth . These experiments are normally set up as for a 
seeded crystallisation study in a metastable solution, 
monitored with a calcium specific ion electrode . Small 
changes in the potential measured by the electrode 
trigger motorized syringes to add equimolar solutions of 
calcium chloride and potassium oxalate so that constant 
calcium and oxalate ionic activities are maintained. The 
growth rate is found from the rate of addition of the 
calcium or oxalate solutions, adjusting for volume 
changes. 
The driving force for crystallisation , (the 
supersaturation), is held constant in this system and 
growth rates are usually linear for more than 30 
minutes, with second order kinetics being obeyed 
(according to equation 4, with [Mt=eql calculated from 
the thermodynamic solubility product) . As has been 
found in conventional seeded systems, the growth rate 
was proportional to the seed crystal concentration 
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(Sheehan & Nancollas, 1980). Crystallisation of the 
trihydrate form of calcium oxalate also followed second 
order kinetics, with a greater rate constant than for the 
monohydrate (Sheehan & Nancollas, 1984). The 
inhibitory effect of urine or defined inhibitors could be 
quantified, as before, by Langmuir adsorption isotherms, 
leading to the inhibitor concentration ( or urinary 
dilution) required to bring about 50% inhibition 
(Sheehan & Nancollas, 1980). In a study comparing 
bladder and kidney urines, and examining the effect of 
various urinary derived macromolecular fractions, simple 
percentage inhibitions were presented (Lanzalaco et al., 
1988). 
The optimal dilution of urine for this method was 
suggested to be 1 % to 2% (Lanzalaco et al., 1982) but 
changes to the electrode design, later permitted use of 
whole urine (Nancollas & Gaur, 1984). A 50% dilution 
of urine reduced the growth rate by 92% of the control 
rate (Gaur & Nancollas, 1984). 
In simple seeded metastable solutions nucleation 
should not be occurring, but this group have been able 
to use their system to see if various factors can promote 
nucleation. In the absence of seed crystals they noted 
the time before any detectable crystallisation began (the 
induction time) (White & Nancollas, 1987; Campbell et 
al., 1989). Aggregation is not considered in this 
method, although, as has already been discussed, this 
may have an indirect effect on growth rates. 
This constant composition approach has a number 
of advantages. It is a better model for the renal 
environment than the systems described above and can 
be operated at lower supersaturations than would be 
used in non seeded conventional crystallisation 
experiments. The constant supersaturation maintains a 
constant driving force for all calcium oxalate hydrates 
crystallising. By contrast, as the different hydrates have 
different solubilities, [Mt]-[Mt=eql will not be the same 
for different hydrates throughout a decaying 
supersaturation experiment. In some circumstances, 
dilution of test components during the procedure might 
be important and the increasing crystal concentration 
may indirectly effect growth and aggregation. 
Mixed Suspension, Mixed Product Removal 
Continuous Crystallisers (Fig. 11 curve g) 
The kidney is a continuous flow system with fresh 
supersaturated urine being continuously formed and 
passed out through the renal pelvis some minutes later 
(Finlayson & Reid, 1978). Finlayson ( 1972) showed 
that this could be described as a series of continuous 
crystallisers. If certain assumptions are upheld, then the 
crystallisation kinetics of a continuous crystalliser can 
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be estimated from the particle size distribution. For the 
theoretical analysis to be valid, the system must be well 
mixed and the outflow must be representative of the 
remaining suspension . This is known as mixed 
suspension, mixed product removal (MSl'v1PR). The use 
of an MSl'v1PR crystalliser to study calcium oxalate 
crystallisation therefore offers the opportunity of 
obtaining physico-chemically meaningful data in a 
crystallizing system which is a better model of kinetics 
of crystallisation in the urine as it flows through the 
kidney. 
A calcium oxalate MSl'v1PR crystalliser usually 
consists of a well mixed chamber with two input feed 
lines and an output line, adjusted to maintain a constant 
volume. Calcium and oxalate are introduced separately 
through the feed lines at equal flow rates and after about 
8-10 chamber volumes have flowed through the system, 
equilibrium is achieved with a stable supersaturation and 
particle size distribution. The average time particles 
remain in the crystalliser is the residence time ('t), 
't = V/Q (19) 
where V is the volume of the chamber and Q is the total 
flow rate into (or out of) the chamber. If the crystals all 
grow at the same rate and aggregation is neglected then 
it can be shown that 
(-L/G-t) 
n = B0-re (20) 
or 
Ln(n) = Ln(Bo-r)-L/G't (21) 
where n is the total number of crystals larger than size 
L, G is the growth rate and Bo is the nucleation rate 
(Rodgers & Garside, 1981). With appropriate units, G 
can be measured as µm/min and Bo as no./min/ml from 
the slope and intercept of the graph of Ln(n) against L, 
according to equation 21. Using the growth and 
nucleation rates it is possible to calculate the suspension 
density (~. in mg/I) according to the following 
equation, 
3 4 -6 
~ = rrpB0G -r x 10 (22) 
where p is the crystal density (g/cm\ 
There have been various applications of the 
MSl'v1PR method, often with components being tested in 
artificial urine (Miller et al. , 1977; Randolph & Drach, 
1981; Li et al., 1985; Kohri et al., 1988 & 1989; 
Robertson & Scurr, 1986). It has also been used with 
dilute urine and macromolecular urinary fractions 
(Drach et al., 1980 & 1982; Springmann et al., 1986). 
MSl'v1PR crystallisers used in urolithiasis research 
are usually much smaller than their chemical 
engineering counterparts and typically have volumes of 
200ml to 400ml. Bearing in mind that about ten times 
this volume must pass through until a steady state is 
obtained, it is clear that only dilute urine could be used 
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in such a system (Springmann et el. (1986) used 5%). 
Recently a much smaller crystalliser with a volume of 
20ml has been developed (Nishio et al ., 1991) and used 
in a study with artificial urine (Nishio et al., 1990). 
This system, applied to nearly whole urine (92%), forms 
the basis of the experimental section of this paper. 
The main disadvantage with the MSMPR system 
is associated with aggregation. If this is significant it 
could invalidate one of the assumptions underlying the 
theoretical analysis of the particle size distribution . In 
practice, if the plot of Ln(n) against L ( as in equation 
21) is linear over most of the size range, then the 
calculated growth and nucleation rates are assumed to 
be realistic. Robertson & Scurr (1986) used the 
deviation from linearity at the extreme values of L, to 
estimate aggregation effects. Springmann et al. (1986) 
added a Couette agglomerator to their system in order 
to study aggregation. Another problem is the relatively 
high feed concentrations of calcium and oxalate that 
must be supplied to the crystalliser. On the other hand, 
it allows measurement of growth and nucleation rates as 
independent parameters and the crystallisation takes 
place in an environment much closer to that of a kidney 
than is found with other systems. 
Concluding Comments on Review Section 
Many different methods have been used to study 
calcium oxalate crystallisation in vitro. Some give a 
general indication of the crystallization potential while 
others are more specifically aimed at measuring growth, 
nucleation or aggregation. In supersaturated, 
crystallising solutions it is not possible to study any one 
of these processes completely in isolation, although 
aggregation alone can be studied in a seeded system at 
equilibrium (Hess et al., 1989). 
The variation in response to a particular treatment 
that might arise in different methods can not easily be 
predicted from consideration of the technical details. 
Unless more than one method is included in an 
investigation then it is always likely to be difficult to 
see the result of one experiment in perspective against 
other studies. For instance, Grover et al. (1990c) using 
two methods concluded that the different results with 
Tamm-Horsfall mucoprotein, as an effector of 
crystallisation of calcium oxalate in urine, depended on 
the method used. 
The main objectives of in vitro calcium oxalate 
crystallisation studies are to evaluate the physico-
chemical response of effectors of crystallisation; to 
investigate mechanisms of stone formation and the role 
of proposed effectors; as a diagnostic tool to identify 
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those at high risk of recurrent disease and to test 
possible treatments a_imed at preventing recurrence. 
When the investigative goals are limited to physico-
chemical evaluation of effectors, then seeded 
crystallisation from a metastable simple salt solution 
may be most appropriate, with the constant composition 
approach having some advantages over supersaturation 
decay methods. 
If the study objectives are directed towards stone 
forming mechanisms, diagnosis or treatment, then the 
relevance of experiments using dilute urine will always 
be questionable. Nevertheless, there are methods which 
employ dilute urine, as well as some which use whole 
urine, which appear to discriminate between stone 
formers and non stone formers and may be of diagnostic 
value, or help in investigation of possible treatments. 
When the methods used are not good models of stone 
formation within the kidney then any differences 
between patient groups must be considered empirical 
and to be without a strong theoretical and mechanistic 
foundation. 
A good in vitro model of stone formation can 
therefore be seen as crucial for improving our 
understanding of the significance of the various 
mechanisms involved and to enable the multitude of 
crysta llisation studies to be put into perspective . No one 
method answers all the requirements of a good model, 
is applicable to whole urine and allows quantifiable 
analysis of nucleation , growth and aggregation. Until 
such a system is devised, different methods with 
different advantages and disadvantages will continue to 
be used. It would be helpful if, in future developments, 
apparently arbitrary differences were kept to a minimum 




Mixed suspension, mixed product removal 
(MSMPR) continuous crystallisation has some 
advantages over other methods commonly applied to 
studies of calcium oxalate crystallisation. Nucleation 
rates can be measured as no./min/ml and growth rates as 
µm/min, independently of each other, but at the same 
time. The method offers a better representation of the 
renal environment than other crystallisation techniques, 
both because it reaches a steady state with a constant 
supersaturation, and because it operates with continuous 
flow; thus, individual crystals only remain in the 
suspension for a relatively short time, not much different 
from transit times through the kidney. 
KAVANAGH, JP. 
Applications of the MSMPR approach have 
previously been limited to artificial urine, with up to 5% 
urine included (Springmann et al., 1986)). The main 
reason for using dilute urine is the volume requirements. 
Most MSMPR crystallisers would need between 2 and 
4 litres of undiluted urine. Our small scale crystalliser 
(Nishio et al., 1991) has a volume of 0.02 litres and 
hence a total feed solution requirement of about 0.2 
litres. 
This experimental section describes some 
experiments to study nucleation and growth rates in 
fresh, minimally diluted urine (by a factor of 1.09) or to 
92% of its initial concentration). 
Materials and Methods 
Urine samples were obtained from healthy men 
with no history of urolithiasis and from male recurrent 
renal stone fonners . Specimens (collected in a pre-
wanned Dewar flask) were adjusted to pH 6.0 with HCl 
or NaOH and analysed for calcium and oxalate. They 
were filtered (8µm cellulose nitrate prefilter (Sartorius 
Ltd.), 0.45µm membrane filter ((Millipore Ltd.), 
perfonned at 37C) or centrifuged {3,000g for 5 minutes 
at 37C). 
This urine (at 37C) was used as one of three feed 
solutions to the continuous crystalliser, pumped at 92% 
of the total flow rate . The other two feed solutions 
were calcium chloride and sodium oxalate , each flowing 
at 4% of the total flow. Knowing the urinary calcium 
and oxalate concentrations, it was possible to adjust 
these two solutions at the start of each experiment to 
give concentrations in the crystallisation chamber (if no 
precipitation occurred) of 12mM calcium and 2.4mM 
oxalate. The experiments were started about 30 minutes 
after the sample was passed and completed about l hour 
later . The crystalliser chamber (see Nishio et al. (1991) 
for details) had a volume of 20ml and was kept at 37C. 
An average residence time ('t) of 6.7 minutes was used. 
When equilibrium had been reached the particle 
size distribution was measured (El zone 80XY, Particle 
Data Inc.) . Crystal growth rates (G, µm/min) and 
nucleation rates (Bo, no./min/ml) were calculated from 
the slope and intercept of the data replotted as Ln no. 
against size (see equation 21). The suspension density 
(M_, mg/I) was calculated using ~uation 22 with the 
crystal density taken to be 2.22g/cm . Occasionally the 
calculated value of M_ exceeded the amount of starting 
material, probably because of errors in estimates of 't 
and B0. To overcome this problem, calculated values of 
M_ were all scaled so that the maximum value 
encountered would give a supersaturation of l. Calcium 
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and oxruate solution concentrations were estimated as 
the difference between their initial concentration and the 
suspension density, other electrolytes were measured 
after the crystallisation experiment and the 
supersaturation calculated using EQUIL2 (Wemess et 
al., 1985). Because of the uncertainty in our estimate of 
M_, we refer to the supersaturation as an index, rather 
than a ratio. 
In a second series of experiments, two crystallisers 
were run simultaneously with the same urine . Fresh 
urine from control subjects was obtained and centrifuged 
as before and divided into two portions. Heparin or 
hyaluronic acid was added to one aliquot. Each portion 
was used as a feed solution for one of the crystallisers. 
Calcium chloride and sodium oxalate solutions were fed 
to each chamber (adjusted to give initial concentration 
of 12mM Calcium and 2.4mM oxalate). In these 
experiments the urinary calcium was taken into account 
but endogenous oxalate was neglected in making up 
these feed solutions. Each concentration examined was 
tested on four different urine samples. 
Oxalate, sulphate and phosphate were measured by 
high perfonnance ion chromatography (HPIC) 
(Robertson & Scurr, 1984); chloride by HPIC at a lower 
dilution; calcium and magnesium by atomic absorption; 
sodium and pota ssium by atomic emission; citrate by 
coupled enzyme assay; ammonium by Berthelot's 
method and osmotic pressure by freezing point 
depression . Hyaluronic acid and heparin were obtained 
from the Sigma Chemical company . Molecular weights 
of 20,000 and 30,000, respectively, were used to 
calculate concentrations. 
The statistical significance of results was assessed 
by analysis of variance (ANOV A), with repeated 
measures when appropriate . Logarithmic 
transfonnations were used for growth and nucleation 
rates to give nonnally distributed data. Including other 
factors, such as urinary ionic strength, in the statistical 
treatment of results allows their influence to be taken in 
account. Multiple linear regression was used to examine 
which additional factors were significant and 
independent and should be included . Tukeys critical 
range test was used to identify significant effects 
(p<0.05) in ANOV As with multiple groups. 
Results 
Comparison of control and stone formers urine. 
Growth rates were found to be almost the same in 
control and stone fonning groups and they did not differ 
between centrifuged and filtered urines (Table 1). 
Nucleation rates were higher in the control samples 
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Table 1. MSMPR growth rates (µm/min) in 92% urine 
from controls (Ctl) and stone formers (SF), centrifuged 
(C) or filtered (F). 
Geometric means (no. of samples) 
centrifuged filtered C and F 
controls 0.65 (10) 0.64 (12) 0.64 (22) 
stone formers 0.65 (10) 0.68 (11) 0.66 (21) 
Ctl and SF 0.64 (20) 0.66 (23) 
Results from ANOV A 
F (d.f.) p 
centifuged 0.3 (1,39) >0.1 
versus 
* filtered 0.1 (1,38) >0.1 
controls 0.2 (1,39) >0.1 
versus 
* stone formers 0.6 (1,38) >0.1 
* 2nd ANOV A adjusts for the initial supersaturation of 
urine samples. 
Table 2. MSMPR nucleation rates x 10·
3 
(no./min/ml) 
in 92% urine from controls (Ctl) and stone formers 
(SF), centrifuged (C) or filtered (F). 
Geometric means (no. of samples) 
centrifuged filtered C and F 
controls 68 (10) 127 (12) 95 (22) 
stone formers 34 (10) 53 (11) 
83 (23) 
43 (21) 
Ctl and SF 48 (20) 
Results from ANOV A 
F (d.f.) p 
centifuged 3.2 (1,39) 0.08 
versus 
* filtered 4.9 (1,38) 0.03 
controls 7.2 (1,39) 0 .01 
versus 
* stone formers 10.7 (1,38) 0.003 
* 
2nd ANOV A adjusts for the initial supersaturation of 
urine samples. 
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Table 3. MSMPR supersaturation indices in 92% urine 
from controls (Ctl) and stone formers (SF), centrifuged 
(C) or filtered (F). 
Means (no. of samples) 
centrifuged filtered C and F 
controls 12.4 (10) 9.8 (12) 11.0 (22) 
stone formers 15.0 (10) 13.7 (11) 14.5 (21) 
Ctl and SF 13.6 (20) 11.7 (23) 
Results from ANOV A 
F (d.f.) p 
centifuged 6.7 (1,39) 0.013 
versus 
* filtered 6.9 (I ,38) 0 .012 
controls 18.8 (1,39) 0.002 
versus 
* 
stone formers 12.5 (1,38) 0.003 
* 
2nd ANOV A adjusts for the ionic strength of urine 
samples. 
compared to the stone formers and higher in samples 
which were filtered rather than centrifuged (Table 2). 
The supersaturation within the crysta lliser was lower in 
control samples than in urines from stone formers and 
lower in filtered urine compared to centrifuged urine 
(Table 3). 
There were factors which our experimental design 
did not control which might have varied between the 
different groups and could, perhaps, explain the 
observed differences in nucleation rates and 
supersaturation. The urinary osmotic pressure (OP), 
ionic strength (IS) and the supersaturation of the whole 
urine samples (S0) were considered as possible 
confounding factors. Their relationship to the 
crystallisation kinetics was investigated. Crystal growth 
rate was significantly related to s0 (p=0.001), OP 
(p=0.040) and IS (p=0.041), but only s0 had a 
significant and independent relationship with growth 
rate. Nucleation rate was significantly related to s0 
only (p=0.015). The supersaturation index was 
significantly related to IS (p=0.025) and OP (p=0.025), 
but only significantly and independently related to IS. 
The significant and independent factor was included in 
a second ANOV A, allowing its influence to be 
discounted. This reinforced the conclusions of the first 
ANOV A (Tables 1-3). 
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Figure 2. The relationship between nucleation rate and growth rate in 92% urine, shown as Ln nucleation rate 
against I/growth rate . The four groups of samples shown are A, controls/ filtered ; B, controls/ centrifuged; C , 
stone former s/ filtered ; D, stone formers/ centrifuged. The intercept s are A, 7.40 ; B, 6.87; C , 6.77; D, 6.08; the 
common slope is 2.72. 
An inverse relationship between the growth rates 
and log nucleation rates was noted. Plots of LnB 0 
against 1/G were significantly correlated (for all 
samples , the correlation coefficient r was 0.7). Analysis 
of variance of the regression data also showed the 
relationship was highly significant (p=0.00001) , with the 
intercepts (p=0 .0006), but not the slopes (p>0 .05) of the 
regression lines being influenced by the type of sample. 
Figure 2 shows the regression lines for the four groups 
of samples . Using Tukeys multiple range test, the 
intercept of the control/ filtered samples was 
significantly greater than the other three samples and the 
intercept of the stone formers/ centrifuged urine was 
significantly lower than the others (p<0 .05) 
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Effect of heparin and hyaluronic acid. 
Heparin and hyaluronic acid were added at various 
concentrations to chamber two while chamber one acted 
as a control in parallel crystalliser experiments. Both 
additives brought about significant dose dependent 
decreases in total crystal numbers , nucleation rate and 
an increase in growth rate (figures 3 and 4). The 
ANOV A revealed overall significant differences 
(p<0 .003) between chamber I and 2, for all parameters 
measured . There was no difference for the control 
experiment (p>0 .05), all three concentrations of heparin 
and the highest two of hyaluronic acid gave significant 
differences (p<0.05) . At the concentrations tested, 
hyaluronic acid was less effective than heparin which 
increased growth rate and decreased crystal numbers by 
nearly 100% (figure 4) . 
CaOx CRYSTALLISATION, METHODS AND APPLICATIONS 
60000 15.0 0.8 A 




* * * 0 7.5 0 





~: I) e ... • ... I) 
': e -0 C • C 
C 0 ...... ... .E - ·;:; C ~: • .E .c ...... .!! -I) ~ E .., ': - u 0 0 ::i. ... ::, C ... >- z C, ... 
0 C 
...J 
0 7.5 0 
2 1 2 2 
Crystallisation chamber 
Figure 3. The effect on crystallisation of A, heparin and B, hyaluronic acid addition to 92% urine in chamber 
2, compared to the same urine without additions in chamber 1. 0, 0µM; e, lµM; □, SµM; ■, IOµM. Each point 
shown is the mean of 4 experiments. * p<0.05 . 
Discussion 
These experiments demonstrate that an MSMPR 
continuous crystalliser system can be applied to nearly 
whole urine (92%). Some preliminary treatment to 
remove any crystals or cellular debris that could act as 
sites for heterogeneous nucleation was considered 
necessary and the effects of filtration and centrifugation 
were studied. In order to compare samples from 
different patients we adjusted all samples to the same 
starting concentrations of calcium and oxalate. The 
concentrations which were used were necessarily 
somewhat higher than physiological, in order to bring 
about sufficient crystallisation. In the absence of 
precipitation very high supersaturation would prevail and 
this provides the thermodynamic driving force for the 
crystallisation. Nevertheless, the steady state 
supersaturation actually achieved within the crystalliser 
was not much higher than is typical of whole urine. 
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The response of urines to this challenging load of 
calcium and oxalate differed between controls and 
recurrent stone formers and also depended to a lesser 
extent on whether the urines had been pre-treated by 
filtration or centrifugation. The mean growth rate did 
not differ between groups but the mean nucleation rate 
was higher in control samples compared to stone 
formers urine . The mass of crystalline material is 
proportional to the product of the cube of the growth 
rate and the nucleation rate and this was higher, and 
hence the supersaturation lower , in the control group. 
This reproduces observations with whole urine in which 
stone formers have often been reported to have higher 
supersaturations than controls (Fleisch, 1978; Robertson 
et al., 1976, 1981). 
The thermodynamic driving force for each sample 
tested would be very similar as they all had the same 
starting concentrations of calcium and oxalate. Their 
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Figure 4. Effects of heparin on crystallisation of calcium oxalate in 92% urine . % change in response, brought 
about by different concentrations added (means of 4 experiments ± s.d.). 
competing mechanisms of supersaturation relief, 
nucleation and growth. This balance can be seen in the 
relationship between LnB0 and 1/G in figure 2. The 
observation that the slopes of these lines are the same 
but the intercepts are different helps to explain the 
difference between the groups of samples. It suggests 
that, for a given value of G, the different groups have 
different values of LnB0 and furthermore , as the log 
differences in B0 are the same for all values of G, then 
the proportional difference in B0 will also be the same. 
Taking the nucleation rate of the control/ filtered 
samples as 100%, then for all values of G, the 
nucleation rates of the other groups will be about 59% 
(control/ centrifuged), 53% (stone formers/ filtered) and 
27% (stone formers/ centrifuged). 
The effect of the higher nucleation rate in the 
control groups is to bring about a lower steady state 
supersaturation and this may be a crucial protective 
factor distinguishing stone formers from controls. Any 
crystals which become temporarily lodged within the 
kidney will have a greater chance of growing and 
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developing into a clinically significant stone when 
growing in a higher supersaturation environment. 
The difference between filtered and centrifuged 
samples is consistent with the widely held belief that 
macromolecular urinary factors are important 
determinants of crystallisation in vivo. These pre-
treatments of the urine are likely to have removed a 
different proportion of high molecular weight factors 
such as Tamm-Horsfall mucoprotein. 
In the experiments with two crystallisers running 
in parallel, we have demonstrated an extension of the 
MSMPR method for examining the effect of potential 
crystallisation effectors, in nearly whole urine. This 
avoids the need for comparing results from different 
urines, which may have widely different compositions. 
In the particular experiments shown, effective 
concentrations of heparin and hyaluronic acid were 
higher than commonly found in other systems. This 
may be because our experiments already include the 
majority of endogenous urinary factors and large doses 
of crystallisation effectors may be needed to bring about 
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further change. Both heparin and hyaluronic acid 
seemed to cause a shift in the balance between 
nucleation and growth in favour of growth, with a net 
increase in supersaturation. 
This method of studying urine in two crystallisers 
simultaneously might be usefully applied to examine the 
in vitro response of urine from a particular individual to 
a proposed therapeutic regime. As any prophylactic 
measures would have to be followed for many years it 
would be extremely useful to establish in advance the 
likely efficacy of the treatment. 
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Discussion with Reviewers 
Reviewer I: How would the authors justify the use of 
such high initial concentrations of calcium and oxalate 
in their MSMPR system? 
Author: Because the system is unseeded, the initial 
supersaturation must be above the metastable limit and 
most MSMPR studies have operated at or above the 
extreme range of physiologically appropriate calcium 
and oxalate concentrations . The concentrations used in 
these experiments were higher than others have worked 
with because of the inhibitory effect of the high urine 
concentration . In order to be able to calculate the 
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growth and nucleation rates. sufficient crystals must be 
generated over a wide particle size range and this could 
only be achieved by employing high initial calcium and 
oxalate concentrations. The steady state solution 
concentrations would, of course, be very much lower. 
Reviewer I: Would not the use of such high 
concentrations produce too high a slurry density (a) for 
counting crystal numbers accurately and (b) for the 
amount of inhibitors and promoters in urine? 
Author: The maximum particle concentration generated 
in the crystallisers was less than {i(),000/ml. The orifice 
tube of the particle sizer had an aperture of 150µm and 
the probability of there being more than one particle at 
a time in the critical volume (three times the aperture 
volume) is <.025, which I feel is an acceptable 
coincidence level. If urinary inhibitors and promoters 
are bound to crystal surfaces, then their effective 
concentration in this system could indeed be 
significantly reduced. This may explain why responses 
to heparin and hyaluronic acid was only found at higher 
concentrations than other workers have observed using 
different experimental techniques. 
Reviewer I: What range of M_ values does the 
authors' system produce? 
Author: The calculated suspension densities (M_) 
ranged from 22 to 775 mg/I. The distribution of values 
was highly skewed with few high values and the mode 
was 183 mg/I. 
Reviewer I: Did the authors find any evidence of 
crystal agglomeration in their studies? If so, how did 
they handle this mathematically? 
Author: Significant agglomeration in the MSMPR 
system would result in non linear particle size 
distributions when plotted as Ln(n) against L. In 
practice we found that good straight lines were always 
obtained for particles up to 30µm in diameter. Beyond 
this size, deviations were sometimes noted but these 
were not very reproducible. Therefore, no attempt was 
made to handle these mathematically. Scanning electron 
microscope images of filtered crystal slurries showed 
well formed calcium oxalate di- and tri- hydrate crystals, 
with no evidence of extensive aggregation. 
B. Hess: At the high concentrations selected, heparin 
and - to a lesser extent - hyaluronic acid in the author's 
MSMPR continuous crystallizer system seem to inhibit 
nucleation rate and to promote crystal growth, which 
might be taken as an attempt to reduce the high 
supersaturation with respect to calcium oxalate present 
in the system. How does this apply to other - naturally 
occurring - urinary inhibitors when tested under the 
same conditions? 
Author: The promotion of growth rate under these 
circumstances may well be a response to the inhibition 
of the nucleation rate, this being the only means of 
supersaturation relief once the nucleation rate has 
diminished. We have no data yet on naturally occurring 
urinary inhibitors but their overall effect in this system 
would be a combination of any direct effects on 
nucleation and growth and their response to the 
supersaturation pressure. Thus a factor which acts as an 
inhibitor of crystal growth in a seeded method may 
appear to promote crystal growth in an MSMPR system. 
H.-G. Tiselius: A higher nucleation rate was recorded 
in urine from control subjects. It is suggested that this 
reflects a protection from forming large crystals and 
could be a distinguishing factor between stone formers 
and normal subjects. Can you speculate on how this 
increased nucleation is achieved? Is this process in any 
way modified by the urine composition? 
Author: It is generally assumed that heterogeneous 
nucleation dominates over homogeneous nucleation in 
vivo (text reference 21) and this is probably true of our 
system as well. Therefore, increased nucleation could 
be achieved either by increasing the number or the 
characteristics of nucleation catalysts. The difference 
between filtered and centrifuged urine samples suggests 
that variation in the concentration of nucleators could be 
an important factor. The urinary composition might 
modify heterogeneous nucleator activity by altering the 
interaction between nucleating crystals and catalyst, 
which will depend on physico-chemical and structural 
factors. There was some evidence of an effect of 
urinary composition in the significant correlation 
(p=0.015) between nucleation rate and the urinary 
supersaturation before the MSMPR experiment was 
started. 
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H.-G. Tiselius: Is there any explanation of the reduced 
nucleation in urine with additives of heparin and 
hyaluronic acid? 
Author: The experimental data shown here do not give 
any direct information on the mechanism of nucleation 
inhibition but adsorption of these macromolecules to the 
surface of heterogeneous nucleators with reduction in 
the interaction between the catalytic surface and 
nucleating calcium oxalate is a plausible explanation. 
